Bafna Pharmaceuticals Ltd.
| BSE: 532989 | Sector: Health care |
| NSE: BAFNAPH | ISIN Code: INE878I01022 |
| BSE 15:48 | 17 May | 127.00 |
-0.05 (-0.04%) |
OPEN
125.00 |
HIGH
127.00 |
LOW
121.50 |
| NSE 15:31 | 17 May | 128.70 |
2.25 (1.78%) |
OPEN
127.00 |
HIGH
132.75 |
LOW
120.70 |
| OPEN | 125.00 |
| PREVIOUS CLOSE | 127.05 |
| VOLUME | 1004 |
| 52-Week high | 190.70 |
| 52-Week low | 115.00 |
| P/E | 27.91 |
| Mkt Cap.(Rs cr) | 300 |
| Buy Price | 127.00 |
| Buy Qty | 31.00 |
| Sell Price | 0.00 |
| Sell Qty | 0.00 |
Bafna Pharmaceuticals Ltd. (BAFNAPH) - Latest News & Headlines
-
Bafna Pharmaceuticals Ltd Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
09/05/2022 | bse |
Downlaod PDF -
Bafna Pharmaceuticals Ltd Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
13/04/2022 | bse |
Downlaod PDF -
Bafna Pharmaceuticals Ltd Certificate From Practicing Company Secretary For The Half Year Ended 31St March 2022
11/04/2022 | bse |
Downlaod PDF -
Bafna Pharmaceuticals Ltd Statement Of Investor Complaints For The Quarter Ended March 2022
07/04/2022 | bse
-
Bafna Pharmaceuticals Ltd Compliance Certificate For The Half Year Ended 31St March 2022
07/04/2022 | bse |
Downlaod PDF
-
Top headlines: Adani group's gross debt, EV fire incidents, and more
7.36 am | 17 May 2022 | Business Standard
From Adani group's gross debt rising to EV fire incidents, here are the top headlines on Tuesday
-
Adani-Holcim deal may trigger consolidation in cement industry: Experts
5.08 am | 17 May 2022 | Business Standard
Expansion plans by most larger players despite glut in markets, fuel price-driven cost pressure and resistance from market to absorb higher cost may f...
-
Adani-Holcim deal may trigger consolidation in cement industry: Experts
5.08 am | 17 May 2022 | Business Standard
Expansion plans by most larger players despite glut in markets, fuel price-driven cost pressure and resistance from market to absorb higher cost may f...
-
Ambuja-ACC deal: Cost synergies seem to justify premium deal valuation
12.38 am | 17 May 2022 | Business Standard
But, whether players maintain discipline or turn aggressive on pricing as new capacities come on stream will be crucial
-
Ambuja-ACC deal: Cost synergies seem to justify premium deal valuation
12.38 am | 17 May 2022 | Business Standard
But, whether players maintain discipline or turn aggressive on pricing as new capacities come on stream will be crucial
Quick Links for Bafna Pharmaceuticals:
-
News
Announcements Brokerage Reports Business Earnings Sector -
Corporate Action
AGM Board Meetings Bonus Dividends EGM Rights Split -
INFORMATION
Bulk Deals Company History MF Holding Listing Info Locations Shareholding -
Financials
Financial Overview Balance Sheet Profit & Loss Cash Flow Ratios Quarterly Results Half Yearly Results Nine Monthly Results Yearly Results -
Annual Report
Auditors Report Chairman's Speech Company Management Directors' Report Finished Goods Raw Materials -
Peer Comparison
Competition Market Cap Price Price Performance Net Sales Net Profit Total Assets Historical Prices
